Review
The heart in scleroderma

https://doi.org/10.1016/0002-9149(66)90246-3Get rights and content

Abstract

“Scleroderma heart disease” is a pathologic rather than a clinical diagnosis. This condition, in its advanced stage, is characterized by widespread proliferation of connective tissue and degeneration of myocardial fibers, but by itself rarely produces significant clinical manifestations. Indeed, when criteria for diagnosis require changes throughout multiple histologic sections, the incidence of “scleroderma heart disease” is low even at necropsy. Only 3 of our 25 necropsy cases of scleroderma met these criteria. Pulmonary and systemic vascular abnormalities played a more important role in disturbing cardiac function. Thus, right ventricular hypertrophy was caused by pulmonary hypertension found alone or in association with pulmonary fibrosis. Left ventricular hypertrophy was caused by malignant systemic hypertension produced by “scleroderma kidney.” The preceding extracardiac factors occurred in all 3 of our cases of “scleroderma heart disease” and caused the major clinical symptomatology.

The most frequent site of cardiac involvement in cases of scleroderma is the pericardium. Pathologically, the commonest lesion is a chronic adhesive pericarditis (36%, of our cases) which does not restrict cardiac filling. Acute pericarditis during the clinial course of the disease is far less frequent than the pathologic lesions would indicate. Large pericardial effusions associated with a relatively normal pericardium histologically may be seen clinically. Minor deformities of the mitral and tricuspid valves occur uncommonly in scleroderma; valvular lesions of hemodynamic significance are due to coexistent rheumatic lesions.

Dyspnea, particularly upon exertion, occurred during the course of the disease in 80 per cent of our cases. It can be generally ascribed to pulmonary hypertension, pulmonary fibrosis, or left heart failure associated with “scleroderma kidney.” It therefore is rarely necessary to invoke “scleroderma heart disease” as a cause for dyspnea.

Right ventricular hypertrophy associated with pulmonary hypertension can be suspected clinically by the loud intensity of the pulmonic component of the second heart sound at Erb's point or by its transmission to the apex and by the presence of a presystolic gallop. There is also a good correlation between the hemodynamic severity of the pulmonary hypertension and the incidence of the electrocardiographic pattern of right ventricular hypertrophy and the roentgenographic analysis of the prominence of the pulmonary artery sector. From a physiologic and pathologic standpoint, the pulmonary hypertension and pulmonary fibrosis appear to be two independent phenomena. It is postuated that pulmonary hypertension in scleroderma is another expression of the heightened vasomotor tone in the disease, namely, Raynaud's phenomenon and “scleroderma kidney.”

Although electrocardiograms and ballistocardiograms are often abnormal in scleroderma, the findings are generally of a nonspecific nature. In only 1 of our 3 cases of “scleroderma heart disease” did the electrocardiogram show an unusual pattern—that of apical infarction. In the 2 remaining cases the pattern of right ventricular hypertrophy dominated in 1 as a result of coexisting pulmonary hypertension, and left ventricular hypertrophy as a result of coexisting systemic hypertension in the other.

In conclusion, “scleroderma heart disease” is an uncommon clinicopathologic entity. Nevertheless, abnormalities of cardiac function in scleroderma often are of major clinical significance because myocardial function is affected secondarily by (1) pulmonary hypertension, (2) systemic hypertension associated with “scleroerma kidney,” (3) pericarditis and pericardial effusion and (4) hypoxia associated with restrictive pulmonary disease.

References (61)

  • F.I. Caird et al.

    The electrocardiogram in diffuse interstitial disease of the lung and its relation to pulmonary function

    Am. J. Cardiol.

    (1962)
  • S. Weiss et al.

    Scleroderma heart disease; with a consideration of certain other visceral manifestations of scleroderma

    Arch. Int. Med.

    (1943)
  • M.A. Sackner et al.

    The pathophysiology of scleroderma involving the heart and respiratory system

    Ann. Int. Med.

    (1964)
  • R. Ashman

    A statistical study of the ventricular gradient and the QRS complex of the electro-cardiogram

    Arch. Inst, cardiol. México

    (1945)
  • B.J. Allenstein et al.

    Evaluation of electrocardiographic diagnosis of ventricular hypertrophy based on autopsy comparison

    Circulation

    (1960)
  • J.M. Barker

    The Unipolar Electrocardiogram; A Clinical Interpretation

  • H.R. Brown et al.

    Clinical Ballisto-cardiography

  • M.M. Aygen et al.

    The splitting of the second heart sound in normal subjects and in patients with congenital heart disease

    Circulation

    (1962)
  • A. Benchimol et al.

    The apex cardiogram in ischemic heart disease

    Brit. Heart J.

    (1962)
  • M. Wolters

    Beitrag zur Kenntniss der Sclerodermie

    Arch. Dermat. u. Syph.

    (1892)
  • A.F. von Notthafft

    Neuere Arbeiten und Ansichten uber Sklerodermie (Zusammenf. Ref. mit Beschreibung eines neuen Falles dieser Krankheit) Als Anhang: Die Zellgewebsverhartung der Neugeborenen

    Zentralbl. allg. Path.

    (1898)
  • R.H. Goetz

    The pathology of progressive systemic sclerosis (generalised scleroderma); with special reference to changes in the viscera

  • R.H. Goetz

    The heart in generalised scleroderma; progressive systemic sclerosis

    Angiology

    (1951)
  • J. Hirayama

    Ein Fall von diffuser Sklerodermie mit hochgradigen Organveranderungen

  • O. Wegelius et al.

    Early cardiac connective tissue changes in scleroderma; report of a case

    Acta med. scandinav.

    (1957)
  • J.T. Roberts

    The heart in connective tissue diseases

  • E.N. Rottenberg

    The heart in progressive systemic sclerosis: A clinical pathologic study

  • J.G. Greenfield et al.

    An Atlas of Muscle Pathology in Neurornuscular Diseases

  • M. Masugi et al.

    Die diffuse Sklerodermie und ihre Gefassveranderung

    Virchows Arch. path. Anat.

    (1938)
  • S. Matsui

    Uber die Pathologie und Pathogenese von Sclerodermia universalis

    Mitt. med. Fak. Tokyo

    (1924)
  • Cited by (91)

    • Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI)

      2013, European Journal of Radiology
      Citation Excerpt :

      However, we believe that the spatial resolution obtained was adequate and that, in addition, the strict criteria used to definite population minimized the possibility of falsely positive areas. In fact, myocardial fibrosis in SSc is different from the findings observed in coronary arteries disease for distribution, form, lack of haemosiderin deposits [24,31] and even for the degree of enhancement at CE-MRI. The CE-MRI identifies fibrotic lesions in the heart of patients with SSc before the evidence of signs recognizable by echocardiogram.

    • Sudden Cardiac Death in Infiltrative Cardiomyopathies: Sarcoidosis, Scleroderma, Amyloidosis, Hemachromatosis

      2008, Progress in Cardiovascular Diseases
      Citation Excerpt :

      In one autopsy study, 6 (13%) of 47 patients died of sudden death.49 The prevalence of electrocardiographic abnormalities in patients with scleroderma is variable, though has been reported to be as high as 85%.50,54-56 Among the most common abnormalities are P-wave notching,52 nonspecific ST-T wave changes,55 right or left ventricular hypertrophy,50,52 and low QRS voltage.52

    • The Heart in Scleroderma

      2008, Rheumatic Disease Clinics of North America
    • Pericardial abnormalities predict the presence of echocardiographically defined pulmonary arterial hypertension in systemic sclerosis-related interstitial lung disease

      2007, Chest
      Citation Excerpt :

      Screening echocardiographic evaluations have shown a prevalence of asymptomatic PEf of 13 to 55%.814151617 The prevalence of symptomatic pericardial abnormalities is much less prevalent, with studies8101112151819 reporting a prevalence of 4 to 16%. To our knowledge, this is the first study to evaluate the prevalence and clinical significance of asymptomatic pericardial abnormalities in patients with SSc-related ILD.

    View all citing articles on Scopus

    This work was supported in part by a grant from the Smith, Kline and French Foundation, a contract Nonr 2744-00 from the Office of Naval Research, Department of the Navy, and Grant H-4797 from the U. S. Public Health Service, Bethesda, Md.

    Present address: Cardio-Pulrnonary Laboratory, Mount Sinai Hospital, Miami Beach, Fla.

    View full text